OTC Markets OTCQB - Delayed Quote USD

NetraMark Holdings Inc. (AINMF)

0.6370

0.0000

(0.00%)

At close: January 22 at 3:00:00 PM EST

Promising TSX Penny Stocks To Consider In December 2024

The Canadian market has recently experienced a pullback, with the TSX index losing about 6.5% since its peak on December 6, amid political uncertainties and year-end profit-taking. Despite this volatility, the underlying economic conditions remain robust, offering opportunities for investors to consider diversifying their portfolios. Penny stocks, while often considered relics of past market eras, continue to present potential value by offering affordability and growth prospects when backed...

Simply Wall St. 30 days ago

ADBRF

BIREF

AINMF
0.00%
NETRAMARK STRENGTHENS FINANCIAL POSITION WITH $1,161,000 RAISED FROM WARRANT AND STOCK OPTION EXERCISE

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is pleased to announce that it has received aggregate proceeds of $1,161,000 from the exercise of 2,244,606 common share purchase warrants (the "Warrants") and 410,000 stock options (the "Stock Options") of the Company, since November 19th, 2024. Following the exercise of the Warrants

CNW Group last month

AINMF
0.00%
NETRAMARK EXPANDS TEAM WITH THE ADDITION OF INDUSTRY VETERAN

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is proud to announce that Angelico Carta, MD, Co-Founder of Worldwide Clinical Trials (Worldwide) will officially consult to NetraMark as Chief Strategy Officer, while continuing in his role as Strategic Advisor to Worldwide.

CNW Group last month

AINMF
0.00%
NETRAMARK SIGNS A PILOT COLLABORATION AGREEMENT WITH A TOP 5 PHARMACEUTICAL COMPANY

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is proud to announce that it has entered into a pilot collaboration agreement with a Top 5 pharmaceutical company. The pilot is seeking to unlock novel insights and hypotheses regarding patient populations to facilitate the development of new therapeutics for autoimmune disorders.

CNW Group last month

AINMF
0.00%
3 TSX Penny Stocks With Market Caps Over CA$30M

Over the last 7 days, the Canadian market has remained flat, but it is up 22% over the past year with earnings forecast to grow by 16% annually. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. These smaller or newer companies can offer great value when built on solid financials, and we've identified three examples that combine balance sheet strength with potential for growth.

Simply Wall St. 2 months ago

AINMF
0.00%
ARREF

GEODF
Top TSX Penny Stocks To Watch In October 2024

Over the last 7 days, the Canadian market has risen by 1.2%, marking a significant 28% increase over the past year, with earnings forecasted to grow by 16% annually. Investing in penny stocks—though now more niche than mainstream—can still provide access to growth opportunities, especially in smaller or newer companies. By focusing on those with strong financials and clear growth trajectories, investors can find promising options among these lesser-known stocks.

Simply Wall St. 2 months ago

AINMF
0.00%
SMDRF

VLTLF
ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (Nasdaq: EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company.

CNW Group 3 months ago

AINMF
0.00%
EXEL
Netramark to Present at the 2024 Cantech Letter Conference in Toronto, ON

Toronto, Ontario--(Newsfile Corp. - October 2, 2024) - NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) (FSE: 8TV) (the "Company" or "NetraMark") a generative AI software leader in clinical trial analytics, is pleased to announce its participation at the upcoming Cantech Letter Conference on Wednesday, October 9, 2024 in Toronto Ontario. George Achilleos, CEO of NetraMark, will be delivering a corporate presentation, where he will provide key insights into NetraMark's AI-driven technology and

Newsfile 3 months ago

AINMF
0.00%
NETRAMARK EXPANDS PRODUCT OFFERINGS TO ADDRESS CORE CLINICAL TRIAL CHALLENGES AND IMPROVE MARKET ACCESS SUCCESS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the expansion of its product base to now include a suite of five innovative offerings designed to enhance clinical trial outcomes, support product differentiation, and optimize market access strategies.

CNW Group 4 months ago

AINMF
0.00%
NETRAMARK PROVIDES Q3 BUSINESS UPDATE AND HIGHLIGHTS PROGRESS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, provides a third quarter business update and highlights recent accomplishments.

CNW Group 5 months ago

AINMF
0.00%
NETRAMARK ANNOUNCES COLLABORATION AGREEMENT WITH NIMH TO ANALYZE CLINICAL TRIAL DATA ON THE USE OF KETAMINE IN PSYCHIATRIC DISORDERS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV), a generative AI software leader in clinical trial analytics, announces that it has entered into a research collaboration agreement with the NIMH (the "Collaboration"). The NIMH is the lead U.S. federal agency for research on mental disorders and is one of the 27 Institutes and Centers that make up the National Institutes of Health (NIH), the largest biomedical research agency in the world. NIH is

CNW Group 7 months ago

AINMF
0.00%
NETRAMARK TO INTRODUCE THE TREATMENT ATTITUDE PROFILE (TAP™) SCALE FOR PLACEBO RESPONSE PERSONA DISCOVERY USING ITS NETRA AI TECHNOLOGY AT THE 2024 ASCP ANNUAL MEETING

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV), a generative AI software leader in clinical trial analytics, is presenting data showing that its TAP™ scale for placebo response persona discovery using the Company's NetraAI technology can help better characterize placebo and drug responders, making it a powerful tool for trialists in their trial design and patient selection strategies. Dr. Joseph Geraci, PhD, Founder, Chief Scientific Officer of

CNW Group 7 months ago

AINMF
0.00%
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces the presentation of new data describing how its proprietary NetraAI clinical trial solution identified novel biomarkers and protein-protein interaction (PPI) pathways associated with specific forms of non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) using small data sets and a self-learning algorithm that obviates

CNW Group 9 months ago

AINMF
0.00%
NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held on March 28, 2024.

CNW Group 9 months ago

AINMF
0.00%
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) is pleased to announce the appointment of Jeff Huntsman to its strategic advisory board. With his significant industry experience and expertise, Jeff's addition to the advisory board will further strengthen NetraMark's ability to deliver its innovative Artificial Intelligence (AI) based offerings and drive business growth.

CNW Group 9 months ago

AINMF
0.00%
NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, provides a business update and highlights recent accomplishments.

CNW Group 9 months ago

AINMF
0.00%
NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces that it has signed a NetraAI Lab contract with a pharmaceutical company (the "Sponsor") to use NetraAI to analyze Phase 2 clinical trial data and deliver key insights and testable hypotheses with the potential to de-risk further development of the Sponsor's asset.

CNW Group 10 months ago

AINMF
0.00%
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces the presentation of new data demonstrating the ability of its proprietary NetraAI clinical trial solution to untangle the intricate web of factors contributing to PD, offering insights applicable to other neurodegenerative disorders, including AD. Application of NetraAI to a dataset of 588 individuals provided by the Michael J.

CNW Group 10 months ago

AINMF
0.00%
NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces that it will present new data demonstrating the potential of its proprietary NetraAI clinical trial solution to generate novel insights into key drivers of Parkinson's disease (PD). The data will be presented in a poster at AD/PD™ 2024 (the International Conference on Alzheimer's and Parkinson's Diseases and related neurological

CNW Group 10 months ago

AINMF
0.00%
NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS

NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces that it has signed a fourth contract in a new indication with a large, publicly listed biopharmaceutical company, pursuant to the Master Service Agreement, previously announced on October 23, 2023.

CNW Group 10 months ago

AINMF
0.00%

Performance Overview

Return	AINMF	S&P/TSX Composite index
YTD	-11.03%	+2.81%
1-Year	+150.79%	+21.07%
3-Year	+39.69%	+22.74%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NetraMark Holdings Inc. (AINMF)

Promising TSX Penny Stocks To Consider In December 2024

NETRAMARK STRENGTHENS FINANCIAL POSITION WITH $1,161,000 RAISED FROM WARRANT AND STOCK OPTION EXERCISE

NETRAMARK EXPANDS TEAM WITH THE ADDITION OF INDUSTRY VETERAN

NETRAMARK SIGNS A PILOT COLLABORATION AGREEMENT WITH A TOP 5 PHARMACEUTICAL COMPANY

3 TSX Penny Stocks With Market Caps Over CA$30M

Top TSX Penny Stocks To Watch In October 2024

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Netramark to Present at the 2024 Cantech Letter Conference in Toronto, ON

NETRAMARK EXPANDS PRODUCT OFFERINGS TO ADDRESS CORE CLINICAL TRIAL CHALLENGES AND IMPROVE MARKET ACCESS SUCCESS

NETRAMARK PROVIDES Q3 BUSINESS UPDATE AND HIGHLIGHTS PROGRESS

NETRAMARK ANNOUNCES COLLABORATION AGREEMENT WITH NIMH TO ANALYZE CLINICAL TRIAL DATA ON THE USE OF KETAMINE IN PSYCHIATRIC DISORDERS

NETRAMARK TO INTRODUCE THE TREATMENT ATTITUDE PROFILE (TAP™) SCALE FOR PLACEBO RESPONSE PERSONA DISCOVERY USING ITS NETRA AI TECHNOLOGY AT THE 2024 ASCP ANNUAL MEETING

NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS

NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS

PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD

NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS

NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE

NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING

NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024

NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS

Performance Overview